Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
COVID-19; Case reference number US-BN-2024-002264 is a spontaneous case initially received from nurse care professional via agency (reference number USBAV24-1809) on 30-Jul-2024 and concerns a patient of unspecified gender or age. The patient's medical history and concomitant medication details were not provided. On unspecified date, as reported recently the patient completed Vivotif vaccination (batch number: unknown), the dose was unknown, orally, for typhoid fever prophylaxis. On unspecified date, as reported of the middle of Vivotif series the patient experienced COVID-19. It was reported that, provider would now like to prescribe an antibiotic to the patient, but they were unsure if it will interact with Vivotif. At the time of initial report, the patient did not recover from event of COVID-19. The reporter assessed the event of COVID-19 as non-serious. The reporter did not provide causality assessment for event of COVID-19. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240730-a837df to US-BAVARIAN NORDIC A/S-US-BN-2024-002264, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown demographics contracted COVID-19, an unknown amount of time after completing Vivotif vaccination. COVID-19 is unlisted and unlabeled per the CCDS v8.0 and USPI for Vivotif. Medical history and concomitant medications were unknown. Considering the highly contagious nature of the SARS-CoV-2 strain, its known human-to-human airborne mechanism of spreading, as well as the lack of biological plausibility, this event is assessed as not related to Vivotif. The case is non-serious.; Sender's Comments: A patient of unknown demographics contracted COVID-19, an unknown amount of time after completing Vivotif vaccination. COVID-19 is unlisted and unlabeled per the CCDS v8.0 and USPI for Vivotif. Medical history and concomitant medications were unknown. Considering the highly contagious nature of the SARS-CoV-2 strain, its known human-to-human airborne mechanism of spreading, as well as the lack of biological plausibility, this event is assessed as not related to Vivotif. The case is non-serious. USBAV24-1809:
Comments: None